Yale University
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Yale University sits in the top decile of US sponsors by registered trial count (#13 of 15,742 sponsors by registered trial count).
Yale University: 1,492 sponsored US clinical trials, 254 recruiting.
Yale University sponsors 1,492 registered US clinical trials on ClinicalTrials.gov, 254 of them currently recruiting, and 1,005 completed. 99 of these trials are in Phase 3-4 (later-stage) and 579 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Opioid Use Disorder, with 19 trials.
Top-decile sponsor footprint
Yale University ranks in the top decile of sponsors by registered trial count (#13 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
1,005 of 1,138 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,492 total, page 7 of 30
Lifestyle, Exercise, and Nutrition Study Early After Diagnosis
NCT03314688
Imaging mGluR5 and Synaptic Density in Psychiatric Disorders
NCT03898297
Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition: Sub-Study II
NCT02710097
Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition: Substudy III
NCT02710331
Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition: Sub-Study I
NCT02709954
Pathogenetic Basis of Aortopathy and Aortic Valve Disease
NCT03440697
Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition
NCT02404688
Cannabinoids, Learning, and Memory
NCT02407808
Enhancing Behavior and Brain Response to Visual Targets Using a Computer Game
NCT02118649
Probing the Cannabinoid System in Individuals With a Family History of Psychosis
NCT02102113
Pilot Study of Gut Commensals in Antiphospholipid Syndrome
NCT01787305
Comparison Between Gastric Band, Laparoscopic Sleeve Gastrectomy, Gastric Bypass Surgeries
NCT02004561
Culturally Adapted Contingency Management
NCT07443332
A Digital Pill System to Measure and Support Acamprosate Adherence in Individuals With Alcohol Associated Liver Disease
NCT07553377
ED PLWD/Care Partner Text Messaging
NCT07423871
Substance Use in Assault-Injured Young Adults
NCT07070414
Health-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For Health
NCT05218980
Effect of HBOT on Femoral Head Avascular Necrosis (AVN)
NCT06931301
Inulin Supplementation for Reducing Inflammation and Knee Pain in Older Adults With Osteoarthritis
NCT07189585
A Virtual Reality E-cigarette Prevention and Emotion Regulation Intervention for Adolescents
NCT07460622
Theoretically Informed Behavioral Intervention
NCT06580184
Pilot Study: Effects of Nimodipine on Alcohol Drinking
NCT06900998
Effects of Nimodipine on Alcohol Drinking
NCT07681869
The Effects of Psilocybin on Social Connectedness
NCT07693153
Psilocybin Microdosing on Cognition, Mood and Quality of Life
NCT07449351
DEPART Study at Yale
NCT07661342
Personal Health Libraries for Formerly Incarcerated Individuals
NCT05441306
Pre-exposure Prophylaxis (PrEP) Adherence for Black MSM
NCT06661343
The Mechanism Underlying the Analgesic Effect of the Music of IBS Pain
NCT06706778
Glucose, Understanding, Integrated Digital Health, and Engagement (GUIDE) Study
NCT07689877
Unified Network for Integrated Fluid Collection at Yale
NCT07689864
Leveraging Chatbot to Improve PrEP in the Southern United States
NCT05968755
Accuracy of the Accuro 3S
NCT07458087
The Impact of Needle Manipulation and Accuracy Between Hand Held Automatic and Traditional Ultrasound Device
NCT05909085
Clinical Trial of Peer Support in the ED (PCORI)
NCT06556069
COMparison Between Anakinra and Tocilizumab in NORSE - "COMBAT-NORSE"
NCT07281027
Psilocybin as a Treatment for Chronic Pain in Smokers
NCT07118332
An Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons With REM Sleep Behavior Disorder (RBD)
NCT06996652
Sex Differences in E-Cigarette Perception
NCT07398976
Survey to Test the Nicotine Concentration and Nicotine Flux Labels for E-cigarettes
NCT07553585
A Clinical Trial of Telehealth Treatment for Opioid Use Disorders
NCT07362082
The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease
NCT07610369
EMS-Initiated Buprenorphine
NCT07475728
Membrane Potential Mapping with18F-TPP
NCT07506616
Pragmatic Trial of Messaging to Providers About Treatment of Chronic Kidney Disease
NCT07430930
Psilocybin-Assisted Physical Therapy in Chronic Low Back Pain
NCT07306364
Promoting Palliative Care for People With Heart Failure
NCT06933875
Adaptive Decision Support for Addiction Treatment (ADAPT) Serial Randomized Testing for Usability, Round 2
NCT07602218
Sac-TMT for Active TNBC Brain Metastases
NCT07458113
Adaptive Decision Support for Addiction Treatment (ADAPT) Serial Randomized Testing for Usability, Round 1
NCT07549126
What is open in the Yale University pipeline
254 recruiting of 1,492 indexed (17% open); 1,005 completed (67%).
Phase mix: 99 late (III/IV) vs 579 early (I/II) (early-phase heavy).
Top condition: Opioid Use Disorder (19 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Yale University: open-pipeline peers nationwide
Peers matched on 1,492 registered trials and 17% open enrollment, not the therapeutic-area sidebar.
Yale University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,492 trials (± recruiting share)
- Washington University School of Medicine · 1,502 trials · 14% recruiting
- Johns Hopkins University · 1,448 trials · 17% recruiting
- University of Pennsylvania · 1,423 trials · 14% recruiting
- Novartis Pharmaceuticals · 1,375 trials · 8% recruiting
Sponsors near 17% open enrollment (± trial volume)
- NYU Langone Health · 17% recruiting · 1,164 trials
- CSL Behring · 17% recruiting · 71 trials
- Penn State University · 17% recruiting · 219 trials
- University of Hawaii · 17% recruiting · 77 trials
Related
What to do with this Yale University page
1,492 registered trials is a research-attention snapshot, not an endorsement of Yale University or any single study.
- 254 of Yale University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Opioid Use Disorder is the condition Yale University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Opioid Use Disorder trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Yale University pipeline card: 1,492 registered trials from official public datasets.Report a data error.